Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.33 |
| ▸ | STS | P08842 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26801638 | 1.00 | SSTR4 (0.39) | SSTR4BRD4TNFJAK3GPR119 | |
| SCHEMBL26654217 | 0.84 | DYRK1A (0.31) | — | |
| SCHEMBL30658026 | 0.81 | SMARCA2 (0.50) | SSTR4BRD4TNFJAK3 | |
| SCHEMBL26654035 | 0.77 | GPR119 (0.34) | GPR119KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL30658031 | 0.77 | GPR119 (0.34) | GPR119KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL26654124 | 0.76 | USP30 (0.37) | SSTR4GPR119NR1H2STSKMT2A | |
| SCHEMBL30658006 | 0.73 | IL1B (0.40) | SSTR4GPR119KMT2AMEN1POLB | |
| SCHEMBL26654138 | 0.73 | IL1B (0.40) | SSTR4GPR119KMT2AMEN1POLB | |
| SCHEMBL30658016 | 0.73 | PDE4B (0.41) | GPR119STSKMT2AMEN1POLB | |
| SCHEMBL26654075 | 0.73 | PDE4B (0.41) | GPR119STSKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302832-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4522279-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220134-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302832-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | BRCA1, VHL, SF3B5 | SSTR4 4127/4885BRD4 159/4885TNF 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.